['overactive bladder']
['solabegron immediate release tablets, low dose', 'solabegron immediate release tablets, high dose', 'matching placebo']

        Inclusion Criteria:

          -  Adult female subjects 18 to 80 years of age, with a ≥ 6-month history of symptoms of
             overactive bladder including: frequency, urgency, and urgency urinary incontinence.
             Subjects must provide written informed consent and either be of non-childbearing
             potential or of childbearing potential meeting specific criteria (e.g., negative
             pregnancy test, sexual inactivity, acceptable methods of birth control, and use of
             hormonal contraceptives).

        Exclusion Criteria:

          -  Subjects must have no history of pelvic or bladder disease, e.g., Grade 3/4 uterine
             prolapse, urogenital malignancy within the past 2 years, surgery for stress
             incontinence or pelvic prolapse repair within the past 6 months, or bladder injections
             with botulinum toxin at any time.

          -  Diabetes insipidus or poorly controlled Type 1 or Type 2 diabetes mellitus

          -  Cardiac conditions: prior cardiovascular events or procedures within 6 months of
             screening; congestive heart failure; abnormal ECG findings, including ECG QT
             correction interval (QTc) > 470 msec at the Screening Visit; systolic blood pressure ≥
             180 mmHg or diastolic blood pressure ≥100mmHg, or heart rate > 100 beats per minute.

          -  Abnormal tests of liver function

          -  History of prior infection due to HIV or hepatitis B or hepatitis C virus

          -  Allergy or hypersensitivity to solabegron or mirabegron

          -  Women of childbearing potential: breastfeeding, pregnant, or actively trying to become
             pregnant

          -  Participation in a trial of an investigational or marketed drug ≤ 30 days prior to the
             Screening Visit or in any clinical trial of an investigational drug that may affect
             urinary function within 3 months prior to Screening Visit.

          -  Inability to read, understand, or complete study-related materials.
      